Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at the Pain Therapeutics Summit in Boston MIAMI, FL ...
(NASDAQ: AMIX) ("Autonomix” or the "Company”), a medical device company focused on advancing precision nerve-targeted treatments, today highlighted positive preliminary results from the first five ...
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral ...